This finding was further supported by the MSKCC cohort study where BAP1 mutations were associated with poor prognostic factors (higher T stage, higher nuclear grade, large size, more necrosis), and the presence of metastatic disease at presentation) [15]. The gene discussed is BAP1; the disease is metastatic neoplasm.